Genomic DNA Cytosine Conversion for Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular diagnostic methods for detecting mutations in genomic DNA, particularly in oncology, face challenges such as false-negative results due to sample contamination or low tumor cell proportions, leading to incorrect treatment decisions and increased costs.
Innovation Solution
A method involving the conversion of cytosines in genomic DNA into uracil, allowing for mutation analysis in converted DNA, which enables the simultaneous detection of mutations and methylation states, thereby improving diagnostic sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional DNA sequencing is used to determine mutations, then the diagnostic process is straightforward, but false-negative results occur due to sample contamination or low tumor cell proportions
Solution Approach 1:
The patent applies preliminary action by performing cytosine conversion (e.g., via bisulfite treatment) on the genomic DNA before conducting mutation analysis. This pre-treatment step modifies the DNA structure to enhance the detectability of mutations, particularly in samples with low tumor cell proportions or potential contamination, thereby improving both reliability and measurement precision in mutation detection
Solution Approach 2:
The patent utilizes parameter changes by altering the chemical state of cytosine residues in the DNA through conversion reactions. This transformation changes the base pairing properties and physical characteristics of the DNA, enabling more sensitive detection of mutations while maintaining the ability to distinguish true positives from false negatives caused by sample contamination or low tumor content
2Reliability
If multiple pathologists assess the sample material to improve accuracy, then false-negative results are reduced, but processing time and personnel expenses increase
Solution Approach 1:
The patent replaces the manual mechanical assessment process performed by multiple pathologists with an automated molecular biology approach. By using cytosine conversion followed by PCR amplification and sequencing, the method achieves high diagnostic accuracy through automated biochemical and computational processes, eliminating the need for multiple manual reviews while reducing processing time and personnel requirements
3Ease of manufacture
If conventional mutation analysis is performed without cytosine conversion, then the procedure is simpler, but the ability to detect mutations in converted DNA is lost
Solution Approach 1:
The patent achieves universality by designing a multi-functional assay that combines cytosine conversion with mutation analysis in a single workflow. The converted DNA can be analyzed using standard PCR and sequencing techniques, making the method broadly applicable to various mutation types and genomic regions while maintaining procedural simplicity. This multi-functional approach eliminates the need for separate assays for different detection needs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity and specificity of molecular diagnostics, allowing for more accurate clinical decision-making and reducing false-negative results, while enabling the analysis of multiple genetic and epigenetic parameters in a single sample, even with limited DNA amounts.
Implementation Method 1
converting at least a part of the cytosines contained in the genomic DNA into uracil or another base having a base pairing behavior and/or molecular weight distinguishable from that of cytosine
Data Source
AI summary
A method for determining a mutation in genomic DNA is described. The method is characterized in that the mutation analysis is performed with genomic DNA, in which at least a part of the cytosines contained therein has previously been converted into uracil or another base with a base pairing behavior or molecular weight distinguishable from that of cytosine.